To meet growing demand, Duke University Eye Center now offers a vast, full-service Ophthalmic Oncology Center that provides a comprehensive approach to diagnosis and treatment for tumors in and around the eye.
The Duke Ophthalmic Oncology Center provides the latest care and treatment for primary ocular tumors, and collaborates with the world-renowned Duke Cancer Institute to address ophthalmic issues related to systemic cancers and their treatments. Duke has one of the few dedicated multidisciplinary patient care and research centers for ophthalmic oncology on the East Coast, and is the major referral center for North Carolina and the surrounding region.
“Our dedicated care team includes top specialists in radiation oncology, medical oncology, pediatric oncology, neurosurgery, neuro-oncology, and pathology,” says Miguel Materin, MD, who leads the center as Director of Ophthalmic Oncology. “We are also working closely with Duke’s new Center for Ocular Immunology, which creates exciting new possibilities for innovative research and treatment.”
Materin joined Duke in 2016 to fulfill the Department of Ophthalmology’s vision to build a premier, extensive program. He previously worked at Wills Eye Hospital and Smilow Cancer Hospital at Yale-New Haven. While at Yale he was responsible for building their robust ocular oncology program. Materin is a member of the Duke Cancer Institute as well as DCI’s Solid Tumor Therapeutics Program and the Cancer Genetics and Genomics Program.
As part of the expansion, Kristen Johnson, PA-C joined Materin’s team in January 2018 from MD Anderson Cancer Center, to assist in directing patient care with both benign and malignant tumors of the eye.
As a result of the center’s move to full-time status, patients experience reduced wait times for services requiring expedited care, Materin notes. The accomplished team has extensive experience diagnosing and treating patients with tumors and conditions like retinoblastoma, uveal melanoma, ocular lymphoma, choroidal hemangiomas, ocular metastases, retinal astrocytic tumors and ocular tumors related to phacomatoses. Where appropriate, the center can also enroll patients in multi-center clinical trials, which will expand and advance treatments for their conditions.
“In recent years, Duke has seen an increased demand for specialty treatment of ocular tumors and eye-related effects of systemic tumors and treatments,” Duke Department of Ophthalmology chair Edward Buckley, MD, notes. “We are thrilled to have Miguel Materin, an internationally respected specialist in this field, here to build a referral program where referring providers and patients can count on the most current and effective treatments in this growing field.”
For questions or to refer a patient, please call Crystal Solomon, ocular oncology program coordinator, at 919.684.8434 or email firstname.lastname@example.org.